NSE · BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹31 Cr with net profit ₹3 Cr — a 8.85% net margin, versus 1.65% the period before.
Shareholding
As of 2026-09-30
- Promoter46.79%
- Public53.13%
- DII0.08%
24,660 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.81× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Trading · ranked #286 of 689 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,35,245 Cr | 130.23 | 3.55 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,05,980 Cr | 66.09 | 7.91 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,45,439 Cr | 79.54 | 20.73 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹91,469 Cr | 343.33 | 63.55 | 13.87% | 2.41% |
| Aditya Infotech Limited | ₹46,574 Cr | 97.58 | 13.8 | 19.61% | 9.77% |
| Aegis Logistics Limited | ₹43,777 Cr | 34.98 | 7.25 | 14.83% | 13.95% |
| Vishal Mega Mart Limited | ₹40,922 Cr | 45.49 | 5.16 | 11.37% | 6.45% |
| Premier Energies Limited | ₹38,736 Cr | 23.26 | 9.29 | 35.05% | 19.67% |
| Redington Limited | ₹28,074 Cr | 15.61 | 2.77 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹14,078 Cr | 55.79 | 9.96 | 14.16% | 9.75% |
| Biofil Chemicals & Pharmaceuticals Ltd.(this company) | ₹47 Cr | 96.2 | 2.13 | 12.92% | 1.4% |
AI analysis
AI-generated · google/gemini-2.5-flashBiofil Chemicals & Pharmaceuticals Ltd. (symbol: 524396) operates in the Pharmaceuticals sector. The company has a market capitalization of Rs 55 Cr and a book value of Rs 13.25. As of March 2026, promoter shareholding is 46.79% with no pledges. The company reported annual revenue of Rs 33.71 Cr in Mar 2025 and a profit margin of 9.79%.
Positives
- +The company has a low debt-to-equity ratio of 0.02, indicating minimal financial leverage.
- +Promoter shareholding is unpledged at 0%, demonstrating no encumbrance on promoter holdings.
- +The latest reported annual ROCE is 14.07%, indicating efficient use of capital.
Negatives
- −Annual revenue decreased by 16.78% from Rs 40.53 Cr in Mar 2024 to Rs 33.71 Cr in Mar 2025.
- −Annual net profit declined by 21.38% from Rs 0.71 Cr in Mar 2024 to Rs 0.56 Cr in Mar 2025.
- −The Price-to-Earnings (PE) ratio is high at 259.08, compared to an EPS of Rs 1.71.
- −DII shareholding declined to 0.08% as of March 2026.
- −Quarterly revenue in Dec 2025 was Rs 0.86 Cr, a significant drop from Rs 13.54 Cr in Sept 2025.
Financial Performance
Biofil Chemicals & Pharmaceuticals Ltd. recorded annual revenue of Rs 33.71 Cr in Mar 2025, a decrease from Rs 40.53 Cr in Mar 2024. Net profit was Rs 0.56 Cr in Mar 2025, down from Rs 0.71 Cr in Mar 2024. The company's earnings per share (EPS) for Mar 2025 was Rs 0.34, compared to Rs 0.44 in Mar 2024.
Profitability & Returns
The company’s profit margin stands at 9.79%. Return on equity (ROE) is 12.92%, and return on capital employed (ROCE) is 14.07%. Net profit in the latest reported quarter (Mar 2026) was Rs 0.21 Cr on revenue of Rs 7.57 Cr.
Balance Sheet
Biofil Chemicals & Pharmaceuticals Ltd. has a low debt-to-equity ratio of 0.02, indicating minimal reliance on borrowed funds. The company's book value per share is Rs 13.25. No details on the company's annual revenue or revenue growth were provided in the JSON data.
Ownership & Pledges
There are no pledged shares by the promoters. The total number of shareholders was 25,356 as of Mar 2026.
Regulatory & Surveillance
The company is not currently under any surveillance measure. There have been no pledged shares reported by the promoters. The DII shareholding has declined to 0.08% as of Mar 2026.
Data as of — price: 2026-10-26 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Biofil Chemicals & Pharmaceuticals Ltd.share price & fundamentals